Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585117 · ClinicalTrials.gov registry record · NA
Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients
A NA study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT00585117 is a NA study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 9 participants.
The verdict
NCT00585117, a NA study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission
Interventions
- PROCEDURE PET Imaging
- PROCEDURE PET imaging
- PROCEDURE PET-imaging with CuATSM
- PROCEDURE PET CuATSM
- PROCEDURE PET imaging with CuATSM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585117
The ClinicalTrials.gov registry entry for NCT00585117 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PET Imaging is the first listed.
NCT00585117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585117 about?
NCT00585117 is a clinical study titled "Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients". Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor ...
What is the current status of trial NCT00585117?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2006-12. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00585117?
The interventions under investigation include: PET Imaging (PROCEDURE), PET imaging (PROCEDURE), PET-imaging with CuATSM (PROCEDURE), PET CuATSM (PROCEDURE), PET imaging with CuATSM (PROCEDURE).
Who is sponsoring clinical trial NCT00585117?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.